Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Inflammation Research
Published in: Inflammation Research 1/2013

01-01-2013 | Original Research Paper

Association of interleukin-1 gene polymorphisms with multiple sclerosis: a meta-analysis

Authors: Jian Huang, Zi-Kang Xie, Rong-Bin Lu, Zheng-Fu Xie

Published in: Inflammation Research | Issue 1/2013

Login to get access

Abstract

Background

Dysregulated levels of interleukin-1 (IL-1) were observed in patients with multiple sclerosis (MS). Previous studies have provided conflicting evidence implicating the IL-1 gene polymorphisms in MS risk.

Methods

A meta-analysis of 16 case–control studies involving 3,482 cases and 3,528 controls was conducted to evaluate this association.

Results

No association was found between the IL-1α −889 (rs1800587), IL-1α +4,845 (rs17561), IL-1β −511 (rs16944), IL-1β +3,953 (rs1143634), IL-1ra variable number tandem repeat (VNTR) polymorphisms and MS risk. However, in subgroup analyses for the IL-1ra VNTR polymorphism, we found that individuals carrying the 2 allele had a 32 % increased risk for bout-onset MS (relapsing remitting and secondary progressive MS) when compared to the LL homozygotes (OR = 1.32, 95 % CI = 1.06–1.66, P z = 0.014).

Conclusion

Common variants in the IL-1 region are not associated with MS risk but our data suggest that the IL-1ra VNTR polymorphism might be associated with bout-onset MS subtype.
Literature
1.
Matsuda M, Tsukada N, Miyagi K, Yanagisawa N. Increased interleukin-1 production by peripheral blood mononuclear cells in patients with multiple sclerosis. J Neurol Sci. 1991;102:100–4.PubMedCrossRef
2.
Imamura K, Suzumura A, Hayashi F, Marunouchi T. Cytokine production by peripheral blood monocytes/macrophages in multiple sclerosis patients. Acta Neurol Scand. 1993;87:281–5.PubMedCrossRef
3.
Cannella B, Raine CS. The adhesion molecule and cytokine profile of multiple sclerosis lesions. Ann Neurol. 1995;37:424–35.PubMedCrossRef
4.
Lamkanfi M, Walle LV, Kanneganti TD. Deregulated inflammasome signaling in disease. Immunol Rev. 2011;243:163–73.PubMedCrossRef
5.
Dinarello CA. Immunological and inflammatory functions of the interleukin-1 family. Annu Rev Immunol. 2009;27:519–50.PubMedCrossRef
6.
Badovinac V, Mostarica-Stojković M, Dinarello CA, Stosić-Grujicić S. Interleukin-1 receptor antagonist suppresses experimental autoimmune encephalomyelitis (EAE) in rats by influencing the activation and proliferation of encephalitogenic cells. J Neuroimmunol. 1998;85:87–95.PubMedCrossRef
7.
Burger D, Molnarfi N, Weber MS, Brandt KJ, Benkhoucha M, Gruaz L, et al. Glatiramer acetate increases IL-1 receptor antagonist but decreases T cell-induced IL-1beta in human monocytes and multiple sclerosis. Proc Natl Acad Sci USA. 2009;106:4355–9.PubMedCrossRef
8.
Erbek SS, Yurtcu E, Erbek S, Atac FB, Sahin FI, Cakmak O. Proinflammatory cytokine single nucleotide polymorphisms in nasal polyposis. Arch Otolaryngol Head Neck Surg. 2007;133:705–9.PubMedCrossRef
9.
García-González MA, Aísa MA, Strunk M, Benito R, Piazuelo E, Jiménez P, et al. Relevance of IL-1 and TNF gene polymorphisms on interleukin-1beta and tumor necrosis factor-alpha gastric mucosal production. Hum Immunol. 2009;70:935–45.PubMedCrossRef
10.
Tarlow JK, Blakemore AI, Lennard A, Solari R, Hughes HN, Steinkasserer A, et al. Polymorphism in human IL-1 receptor antagonist gene intron 2 is caused by variable numbers of an 86-bp tandem repeat. Hum Genet. 1993;91:403–4.PubMedCrossRef
11.
Crusius JB, Peña AS, Van Oosten BW, Bioque G, Garcia A, Dijkstra CD, et al. Interleukin-1 receptor antagonist gene polymorphism and multiple sclerosis. Lancet. 1995;346:979.PubMedCrossRef
12.
Huang WX, He B, Hillert J. An interleukin 1-receptor-antagonist gene polymorphism is not associated with multiple sclerosis. J Neuroimmunol. 1996;67:143–4.PubMedCrossRef
13.
de la Concha EG, Arroyo R, Crusius JB, Campillo JA, Martin C, Varela de Seijas E, et al. Combined effect of HLA-DRB1*1501 and interleukin-1 receptor antagonist gene allele 2 in susceptibility to relapsing/remitting multiple sclerosis. J Neuroimmunol. 1997;80:172–8.PubMedCrossRef
14.
Schrijver HM, Crusius JB, Uitdehaag BM, García González MA, Kostense PJ, Polman CH, et al. Association of interleukin-1beta and interleukin-1 receptor antagonist genes with disease severity in MS. Neurology. 1999;52:595–9.PubMedCrossRef
15.
Sciacca FL, Ferri C, Vandenbroeck K, Veglia F, Gobbi C, Martinelli F, et al. Relevance of interleukin 1 receptor antagonist intron 2 polymorphism in Italian MS patients. Neurology. 1999;52:1896–8.PubMedCrossRef
16.
Kantarci OH, Atkinson EJ, Hebrink DD, McMurray CT, Weinshenker BG. Association of two variants in IL-1beta and IL-1 receptor antagonist genes with multiple sclerosis. J Neuroimmunol. 2000;106:220–7.PubMedCrossRef
17.
Ferri C, Sciacca FL, Grimaldi LE, Veglia F, Magnani G, Santuccio G, et al. Lack of association between IL-1A and IL-1B promoter polymorphisms and multiple sclerosis. J Neurol Neurosurg Psychiatry. 2000;69:564–5.PubMedCrossRef
18.
Luomala M, Lehtimäki T, Elovaara I, Wang X, Ukkonen M, Mattila K, et al. A study of interleukin-1 cluster genes in susceptibility to and severity of multiple sclerosis. J Neurol Sci. 2001;185:123–7.PubMedCrossRef
19.
Niino M, Kikuchi S, Fukazawa T, Yabe I, Sasaki H, Tashiro K. Genetic polymorphisms of IL-1beta and IL-1 receptor antagonist in association with multiple sclerosis in Japanese patients. J Neuroimmunol. 2001;118:295–9.PubMedCrossRef
20.
Mann CL, Davies MB, Stevenson VL, Leary SM, Boggild MD, Ko Ko C, et al. Interleukin 1 genotypes in multiple sclerosis and relationship to disease severity. J Neuroimmunol. 2002;129:197–204.PubMedCrossRef
21.
Hooper-van Veen T, Schrijver HM, Zwiers A, Crusius JB, Knol DL, Kalkers NF, et al. The interleukin-1 gene family in multiple sclerosis susceptibility and disease course. Mult Scler. 2003;9:535–9.PubMedCrossRef
22.
Dincić E, Zivković M, Stanković A, Obradović D, Alavantić D, Kostić V, et al. Association of polymorphisms in CTLA-4, IL-1ra and IL-1beta genes with multiple sclerosis in Serbian population. J Neuroimmunol. 2006;177:146–50.PubMedCrossRef
23.
Sarial S, Shokrgozar MA, Amirzargar A, Shokri F, Radfar J, Zohrevand P, et al. IL-1, IL-1R and TNFalpha gene polymorphisms in Iranian patients with multiple sclerosis. Iran J Allergy Asthma Immunol. 2008;7:37–40.PubMed
24.
Aggelakis K, Zacharaki F, Dardiotis E, Xiromerisiou G, Tsimourtou V, Ralli S, et al. Interleukin-1B and interleukin-1 receptor antagonist gene polymorphisms in Greek multiple sclerosis (MS) patients with bout-onset MS. Neurol Sci. 2010;31:253–7.PubMedCrossRef
25.
Borzani I, Tola MR, Caniatti L, Collins A, De Santis G, Luiselli D, et al. The interleukin-1 cluster gene region is associated with multiple sclerosis in an Italian Caucasian population. Eur J Neurol. 2010;17:930–8.PubMedCrossRef
26.
Mirowska-Guzel D, Gromadzka G, Mach A, Czlonkowski A, Czlonkowska A. Association of IL1A, IL1B, ILRN, IL6, IL10 and TNF-α polymorphisms with risk and clinical course of multiple sclerosis in a Polish population. J Neuroimmunol. 2011;236:87–92.PubMedCrossRef
27.
Poser CM, Paty DW, Scheinberg L, McDonald WI, Davis FA, Ebers GC, et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol. 1983;13:227–31.PubMedCrossRef
28.
McDonald WI, Compston A, Edan G, Goodkin D, Hartung HP, Lublin FD, et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol. 2001;50:121–7.PubMedCrossRef
29.
Polman CH, Reingold SC, Edan G, Filippi M, Hartung HP, Kappos L, et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria”. Ann Neurol. 2005;58:840–6.PubMedCrossRef
30.
Nikolopoulos GK, Masgala A, Tsiara C, Limitsiou OK, Karnaouri AC, Dimou NL, et al. Cytokine gene polymorphisms in multiple sclerosis: a meta-analysis of 45 studies including 7379 cases and 8131 controls. Eur J Neurol. 2011;18:944–51.PubMedCrossRef
31.
Han B, Eskin E. Random-effects model aimed at discovering associations in meta-analysis of genome-wide association studies. Am J Hum Genet. 2011;88:586–98.PubMedCrossRef
32.
Hurme M, Santtila S. IL-1 receptor antagonist (IL-1Ra) plasma levels are co-ordinately regulated by both IL-1Ra and IL-1beta genes. Eur J Immunol. 1998;28:2598–602.PubMedCrossRef
Metadata
Title
Association of interleukin-1 gene polymorphisms with multiple sclerosis: a meta-analysis
Authors
Jian Huang
Zi-Kang Xie
Rong-Bin Lu
Zheng-Fu Xie
Publication date
01-01-2013
Publisher
SP Birkhäuser Verlag Basel
Published in
Inflammation Research / Issue 1/2013
Print ISSN: 1023-3830
Electronic ISSN: 1420-908X
DOI
https://doi.org/10.1007/s00011-012-0556-1

Other articles of this Issue 1/2013

Inflammation Research 1/2013 Go to the issue

Original Research Paper

Fractionated irradiations lead to chronic allergic airway inflammation through increasing the influx of macrophages

Original Research Paper

Changes in serum cytokine and cortisol levels in normothermic and hypothermic term neonates after perinatal asphyxia

Original Research Paper

Anti-inflammatory and anti-arthritic activities of 3,4-dihydro-2,2-dimethyl-2H-naphthol[1,2-b]pyran-5,6-dione (β-lapachone)

Original Research Paper

FcγRIIa requires lipid rafts, but not co-localization into rafts, for effector function

Original Research Paper

Effect of tonsillar mononuclear cell supernatants in patients with IgA nephropathy on renal tubular epithelial cells

Original Research Paper

Anti-arthritic activity of the Indian leafy vegetable Cardiospermum halicacabum in Wistar rats and UPLC–QTOF–MS/MS identification of the putative active phenolic components
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits